

DAFTAR PUSTAKA

1. Lindenstrom E, Baysen G, Nayboe J, Applyard M. *Stroke incidence in Copenhagen, 1976-1988*. *Stroke* 1992; 23: 28-32.
2. Bonita R. Epidemiology of stroke. *Lancet*, 1992; 339: 342-49.
3. Broner L, Kanter DS, Manson JE. primary prevention of stroke. *New Engl J Med*, 1995; 23; 1392 - 1400.
4. Hachincki V, Norris WJ, The Acute Stroke. Philadelphia; *FA Davis Company*, 1985.
5. Hsu CY, Norris JW, Hogan EL, Bladin P, Dinsdale HB, Yat su F et al. Pentoxifylline in acute non hemorrhagic stroke. A randomized placebo-controlled double-blind trial. *Stroke*, 1988; 19: 716-22.
6. Collins RC, Dobkin BH, Choi DW. Selective vulnerability of the brain; New insight into pathophysiology of stroke. *Ann Inter Med*, 1998; 110:982-1000.
7. Fiesco C, Agentino C, lenzi GL. Clinical Instrumental evaluation of patients with ischaemic stroke within first six hours. *J Neurol Sci*, 1989: 91: 311-22.
8. Koller M, Haenny P, hess K, Weniger D, Zagger P. Adjust. Hypervolemic hemodilution in acute ischemic stroke. *Stroke*, 1990: 21: 1429-34.
9. Hacke W, Hennerici M, gelters HJ, Kramer G. Cerebral Ischemia. *Berlin: Sringer-Vrelag*, 1993.
10. Strand T. Evaluation of long term outcome and safety after hemodilution therapy in acute ischemic stroke. *Stroke*, 1992; 23: 657-62.
11. Mohr JP, Orgogozo JM, Hennerici M, Wahlgren NG, Gelters JH, Martinez-Vila E et al. Meta-analysis of Oral nimodipine trials in acute ischemic stroke. Preprint cerebrovascular diseases. *Basel: Karger Ag*, 1994.
12. Budiarmo LR, Bakri Z, Kortani DS. Morbiditas dan

13. Lamsudin R, Dahlan P, Damodoro N, Sutami S. Laporan Penelitian proporsi Penderita Stroke di Yogyakarta, Lembaga Penelitian Universitas Gadjah mada Yogyakarta, 1989.
14. Martono M, Lamsudin R. Morbidity of stroke in Yogyakarta, Indonesia, Januari 1, 1991 trough December 13, 1991. Presented on First Asian-Ocenian Symposium in Neuroepidemiology and Second Wu Ho - Su memorial Lecture 1994, Taipei.
15. Hu HN, Sheng WY, Chu FL, Lan CF, Chiang BN. Incidence of stroke in Taiwan. *Stroke*, 1992; 23: 1237 - 41.
16. Basim BA, Shamenna AR, Kolawole TM, Patel PJ. Cerebrovaskuler disease in Saudi Arabia. *Stroke*, 1991; 22: 1173-76.
17. Sam Permana wati, Lamsudin R. Mortalitas Stroke di RSUP Dr. Sardjito Yogyakarta tahun 1986-1989. Dipresentasikan pada Pertemuan Nasional Dwi Warsa II IDASI, 1990, Yogyakarta.
18. Basuki S, dan Lamsudin R. Mortality of Stroke in Yogyakarta, Indonesia, Januari 1, 1991 through December 31, 1991. Presented on First Asian-Ocenian Symposium in Neuroepidemiology and Second Wu Ho - Su memorial Lecture, 1994, Taipei.
19. Feigenson JS, Feigenson WD. Outcome and cost for stroke patient in Academic and Community Hospitals. *JAMA*, 1978; 240: 1878-80.
20. Tanaka H. Secular trend in mortality for cerebrovaskuler disease in Japan, 1960-1979. *Stroke*, 1982; 13: 574-81.
21. Silver FL, Norris JW, Lewis AJ. Early mortality following stroke. A Prospective review. *Stroke*, 1984; 15: 492-96.
22. Chang CC, Chen CJ. Secular trend of mortality from cerebral infarktion and cerebral hemorrhage in Taiwan, 1974-1988. *Stroke*, 1993; 24: 212-18.
23. Dykewn ML, Wolf PA, barnett HJM, bergan JJ, Sundt TH. Risk factors in stroke: A statement for physicians by subcommitee 1984; 15: 1105-111.
24. Lamsudin R. Risk factor for stroke among bank employee in Yogyakarta. Presented in Congress IEA 1990. Los

25. Lamsudin R. Well controlled and Less well controlled hypertension in stroke patients in Yogyakarta. M.Med. Sc's Thesis. University of new Castle, Australia, 1993.
26. Collins R, Mac Mahon S. Blood pressure, antihyperrensic drug treatment and the risk of stroke and of coronary heart disease. *Br Med Bull*, 1994; 50: 272-98.
27. Darmoyo RB. Beberapa data epidemiologik hipertensi di Jawa Tengah. *Medika*, 1977; 50: 272-98.
28. Permanawati S, Lamsudin R, Djokorijanto D, Umam R. Fibrinogen sebagai faktor risiko stroke di RSUP Dr. Sardjito Yogyakarta. Dibacakan pada Konggres Nasional II IDASI, 1994, Bandung.
29. Jamrozik K, Broadhurst RJ, Anderson CS, Steward Wyne FG. The role of lifestyle in the etiology of stroke. A population-based case-control study in Perth, Westren Australia. *Sroke*, 1994; 25: 51-8.
30. Mac Mahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. *J Hypertens, Suppl*, 1994; 12: 25-14.
31. Jorgensen H, Nakayama H raaschou HO, Olsen TS. Intra cranial hemorrhage versus infraction : stroke severity, risk factors, and prognosis. *Ann Neurol*. 1995 , 26 : 45-50.
32. Juvela S, Hillbom M, Palomaki H. Risk factors spontaneous intracerebral hemorrhage. *Stroke*, 1995, 26 : 1558-64.
33. Jorgensen H, Nakayama H raaschou HO, Olsen TS. Sroke in patient with diabetes. The Copenhagen Stroke Study. *Stroke*, 1994; 25: 1977-84.
34. Tuomilehto J. Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes millitus as a risk factor for death from stroke. Prospective study of the middle-aged finish population. *Stroke*, 1996; 27: 210 - 5.
35. Lebto S, Ronnëmaa T, Pyrola K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin dependent diabetes. *Stroke*, 1996; 27: 63-8.
36. Mast H, Thomson JL, Lee SH, Mohr JL, Sacco RL. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. *Stroke* 1988; 19: 1359-1364.

37. Woo E, Ma JTC, Robinson JD, Yu YL. Hyperglycaemia is stress response in acute stroke. *Stroke* 1988; 19: 1359-1364.
38. Eliasziw M, Streifler JY, Spence JD, Fox AJ, Hachinski VC, Barnett HJ. Prognosis for patients following a transient ischaemic attack with and without a cerebral infarction on brain CT. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. *Neurology* 1995; 45: 428-31.
39. Brainin M, Mc Shane LM, Steiner M, Dachenhausen A, Seiser A. Silent brain infarcts and transient ischemic attack. A three year study of first-ever ischemic stroke patients: the Klosterbeurg Stroke Data Bank. *Stroke* 1995; 26: 1348-52.
40. Tanaka H, Hajashi M, Date C, Umam K, Asada M, Shoji H, Okazaki K, Yamamoto H, Yoshikawa K, Shimato T. Epidemiologic studies of stroke in Shibata, a Japanese Provincial City. Preliminary report on risk factor for cerebral infarction. *Stroke* 1985; 5: 773-80.
41. Gorelick PB. Stroke prevention: an opportunity for efficient Utilization of health care resources during the coming decade. *Stroke*, 1994; 25: 220-224.
42. Gorelick PB. Stroke Prevention. *Arch Neurol*, 1995; 52: 347-355.
43. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action : a statement for healthcare professional. *Circulation*, 1997; 95: 1085 - 1090.
44. Davis PH, Dambrosia JM, Schoenberg BS, Risk factors for ischemic stroke : a prospective study in Rochester, Minnesota. *Ann Neurol*, 1987; 22: 319-327.
45. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. For the Framingham Study. Stroke risk profile: adjustment for antihypertensive medication. *Stroke*, 1994; 25: 40-43.
46. Burt VL, Whelton P, Rocella EJ. Prevalence of hypertension in the US adult population: result from the third National Health and Nutrition Examination Survey, 1988-1991. *Hypertension*, 1995; 305-313.

47. The Sixth report of Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Arch Intern Med*, 1997; 157: 2413-2446.
48. Collins R, Peto R, Mac Mahon S. Blood pressure, stroke, and coronary heart disease, part 2: shortterm reductions in blood pressure: overview of randomized drug trials in their epidemiological context. *Lancet*, 1990; 335: 827-838.
49. SHEP cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP), *JAMA*, 1991; 265: 3255-3264.
50. Messerli F, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in elderly? A systematic review. *JAMA*, 1988; 279: 1903-1907.
51. 4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, Tucson, Arizona, April 1995, Proceedings. *Chest*, 1995; 108 (Suppl 4): 225S-522S.
52. Tanne D, Golbourt U, Zion M, Reicher-Reiss H, Kaplinsky E, Behar S. For the SPRINT study Group. Frequency and prognosis of stroke/TIA among 4808 survivors of acute myocardial infarction. *Stroke*, 1993; 24: 1490-1495.
53. Loh E, Sutton Ms, Wun CC. Ventricular dysfunction and the risk of stroke after myocardial infarction. *N Engl J Med*, 1997; 336: 251-257.
54. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. *Chest*, 1998; 114: 611-633.
55. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombotic therapy for ischemic stroke. *Chest*, 1998; 114: 683-698.
56. Matchar DB, Mc Croy DC, Barnett HJ, Feussner JR. Medical treatment for stroke prevention. *Ann Intern Med*, 1994; 121: 41-52.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

57. Ryan TJ, Anderson JL, Antman EM. For the Committee on Management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*, 1996; 28: 1328-1428.
58. Eccles M, Freemantle N, Mason J. For the North of England Aspirin Guidelines Development Group. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. *BMJ*, 1998; 316: 1303-1309.
59. Report of the Sixty Plus Reinfarction Study Research group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. *Lancet*. 1980; 2: 989-994.
60. Smith P, Arnessen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. *N Engl J Med*, 1990; 323: 147-152.
61. Anticoagulants in the Secondary Prevention of Event in coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. *Lancet*, 1994; 343: 499-503.
62. European Atrial Fibrillation in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. *N Engl J Med*, 1995; 333: 5-10.
63. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trial of antiplatelet therapy, I prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories patients. *BMJ*, 1994; 308: 81-106.
64. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*, 1994; 344: 1383-1389.
65. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long Term Intervention with Pravastatin in ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. *Am J Cardiol*, 1995; 76: 1000-1006.

1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025

1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025

1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025

1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025

66. Sacks FM, Pfeffer MA, Moye LA. For the cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med*, 1996; 335: 1001-1009.
67. Expert Panel on detection, Evaluation, and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel II). Summary of the second report of the National Cholesterol Education Program (NCEP). *JAMA*, 1993; 269: 3015-3023.
68. Sacco RI, Benjamin EJ, Broderick JP, American Heart Association Prevention Conference, IV: prevention and rehabilitation of stroke, risk factor. *Stroke*, 1997; 28: 1507-1517.
69. Gorelick PB, Schneck EJ, Berglund LF, Feiberg W, Goldstone J. Status of lipids as risk factor for stroke. *Neuroepidemiology*, 1997; 16: 107-115.
70. Wolf PA, Dawber TR, Thomas HEJ, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. *Neurology*, 1978; 28: 973-977.
71. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*, 1991; 22: 983-988.
72. The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. *Arch Intern Med*, 1997; 157: 1237-1240.
73. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: *Arch Intern Med*, 1994; 154: 1449-1457.
74. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. *Chest*, 1995; 108: (suppl 4): 352S-359S.
75. Prystowsky EN, Benson DWJ, Fuster V. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Management of patient with atrial fibrillation: a statement of healthcare professional. *Circulation*, 1996; 93: 1263-1277.
76. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson Ak, Singer DE. Antithrombotic therapy in atrial fibrillation. *Chest*, 1998; 114: 579-589.

1951
MAY 13 1951

1951
MAY 13 1951

1951
MAY 13 1951

1951
MAY 13 1951

1951
MAY 13 1951

1951
MAY 13 1951

1951
MAY 13 1951

1951
MAY 13 1951

77. Report of Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: stroke prevention in patients with nonvalvular atrial fibrillation. *Neurology*, 1998; 51: 671-673.
78. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. *Neurology*, 1998; 51: 674-681.
79. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from Framingham Study. *Stroke*, 1991; 22: 312-318.
80. Kuller LH, Dorman JS, Wolf PA. Cerebrovascular disease and diabetes. In: National Diabetes Data Group Department of Health and Human Services, National Institutes of Health, ed. Diabetes in America: Diabetes Data Compiled for 1984; Bethesda, Md, Conn : Appleton & Lange, 1996.
81. report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, 1997; 20: 837-853.
82. Effect of intensive diabetes management on macrovascular events and risk factor in the Diabetes Control and Complication Trial. *Am J Cardiol*, 1995; 75: 894-903.
83. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of macrovascular and microvascular complication in Type 2 diabetes : UKPDS 33, *Lancet*, 1998; 352: 837-853.
84. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. *N Engl J Med*, 1993; 329: 977-986.
85. Abbott RD, Yin Y, Read DM, Yano K. Risk of stroke in male cigarette smokers. *N Engl J Med*, 1986; 315: 717-720.
86. Bonita R, Scragg R, Stewart A, Jackson R, Beaglehole R. Cigarette smoking and risk of premature stroke in men and women. *BMJ*, 1986; 293: 6-8.
87. Colditz GA, Bonita R, Stampfer MJ, Cigarette smoking and risk of stroke in middle-aged women. *N Engl J Med*, 1988; 318: 937-941.

100

100

100

100

100

100

100

100

100

100

100

100

88. Gorelick PB, Rodin MB, Langenberg P, Hier DB, Costigen J. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: results of a case-control study at three urban medical centers in Chicago, Illinois. *Neurologi*, 1989; 38: 339-343.
89. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ*, 1989; 298: 789-704.
90. Wolf PA. Cigarettes, alcohol, and stroke. *N Engl J Med*, 1986; 315: 1087-1089.
91. heiss G, Sharrett Ar, Barnes R, Chambless LE, Szklo M, Alzola C. carotid atherosclerosis measured by B-mode ultrasound in populations: association with cardiovascular risk factors in the ARIC study. *Am j Epidemiol*, 1991; 134: 250 - 256.
92. O'Leary DH, Polak JF, Kronmal RA. Sistribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. *Stroke*, 1992; 23: 1752-1760.
93. Sacco RL, Robers JK, Boden-Albala B. Race-ethnicity and determinants of carotid artery stenosis in Hispanic, black, and white patients with stroke or transients ischemic attack. *Stroke*, 1998; 29: 980-912.
94. Mast H, Thompson JL, Lin IF. Cigarette smoking as determinant of high-grade carotid artery stenosis in Hispanic, black, and white patients with stroke or transients ischemic attack. *Stroke*, 1998; 29: 980-912.
95. Wannmethee SG, Sharper AG, Whincup PH, Walker M. Smoking cessation and risk of stroke in middle aged men. *JAMA*, 1995; 274: 155-60.
96. Flecher GF. Exercise in the prevention of stroke. *Health rep*, 1994; 6: 106-110.
97. Manson JE, rimm EB, Stampfer MJ. Physical activity and incidence of non-insulin dependent diabetes mellitus in women. *Lancet*, 1991; 338: 774-778.
98. Kokkinos PF, Narayan P, Colleran JA. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with ever hypertension. *N Engl J Med*, 1995; 333: 1462-1467.

99. Blair SN, Kampert JB, Kohl HW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all acute mortality in men women, *JAMA*, 1996, 276 : 205 - 210.
100. Lakka TA, Salonen JT. Moderat to high intensity conditioning leisure time physical activity and high cardiorrespiratory fitness are associated with reduced plasma fibrinogen in eastern finnish men, *J Clin Epidemiol*, 1993 : 46 : 1119-1127.
101. Wang JS, Jen CJ, Chen HI, Effect of exercise training and deconditioning on platelet function in men, *Arterioscler Throm Vasc Biol*, 1995, 15 : 1668-1674.
102. William PT, High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners, *N Engl J Med*, 1996, 334 : 1298-1303.
103. Stamler J, Rose G, Stamler R, Elliot P, Dter A, Marmot M. INTERSALT study findings : public health and medical care implications, *Hypertension*, 1989, 14 : 571-577.
104. Gillman MW, Cupples LA, Gagnon D. Protective effect of fruits and vegetables on development of stroke in men, *JAMA*, 1995, 71 : 1113 - 1117.
105. Gey KF, Stahelin HB, Eicholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and strke, *Clin Invest*, 1993 , 71 : 3 - 6.
106. Khaw KT, Barrett-Connor E. Dietary potasium and stroke associated mortality : a 12 year prosective population study, *N Engl J Mel*, 1987, 316 : 235 - 240.